Skip to main content
. 2018 Jun 18;9(7):715. doi: 10.1038/s41419-018-0743-2

Fig. 8. Analysis of potential side effects for treatment of RA-V.

Fig. 8

a–b The change curves of body weights of BALB/c bearing HCT116 (a) or HepG2 (b) xenograft tumors (n = 8 or 7). c Representative hematoxylin–eosin staining of heart, kidney, spleen, lung, and liver from vehicle- and various concentrations of RA-V-treated group. d The evaluation of serum ALT, AST, and creatine kinase for vehicle- and various concentrations of the RA-V-treated group